Please ensure Javascript is enabled for purposes of website accessibility

Why Tricida Stock Is Jumping Today

By Keith Speights – Nov 16, 2021 at 11:38AM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker announced a stock and warrant offering.

What happened

Shares of Tricida (TCDA 4.59%) were jumping 11% higher as of 11:23 a.m. EST on Tuesday. The solid gain came after the company announced that it had entered into definitive agreements to sell stock and warrants that will generate gross proceeds of around $42 million.

So what

It's par for the course for drugmakers to raise additional capital through issuing new shares and/or warrants. What's unusual is for a biotech stock to rise on the news instead of fall. Selling additional shares and warrants leads to dilution in the value of existing shares, which isn't good news for shareholders.

A scientist looking through a microscope.

Image source: Getty Images.

So why did Tricida's shares move higher today? Investors are likely encouraged because the price of the offering was well above the 30-day volume-weighted average share price of $4.69 and the closing price of $5.46 on Friday. This indicates that the buyers of the new shares and warrants (who have already been lined up) are quite bullish about the company's prospects.

Of course, there's also the fact that Tricida will have more money to fund its clinical programs. The company said that it intends to use part of the funds to continue testing its experimental drug veverimer in a study targeting chronic kidney disease.

Now what

Tricida expects to report top-line results from its renal outcomes clinical trial of veverimer in the third quarter of 2022. The company thinks that the proceeds from its stock and warrant offering will fund operations for around six months afterward.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.